Integrating Artificial Intelligence into Drug Development and Manufacturing: Advancements and Challenges

Mayuri.R.Mandlik*[1], Pathan.N.Hakimkhan*[2], Punam.B.Mahanor*[3]

*[1]Student, PratibhataiPawar College Of Pharmacy, Shrirampur
*[2]Assistant Professor, PratibhataiPawar College Of Pharmacy, Shrirampur
*[3]Student, PratibhataiPawar College Of Pharmacy, Shrirampur
Corresponding Author: Mayuri.R.Mandlik

ABSTRACT: The integration of Artificial Intelligence (AI) into drug development and manufacturing is Revolutionizing the pharmaceutical industry, offering advancements in efficiency, precision, and Cost reduction. This review article explores the importance of AI in accelerating drug discovery, Enhancing precision medicine, streamlining clinical trials, and optimizing manufacturing Processes. By leveraging machine learning, natural language processing, and robotics, AI enables Accelerated target identification, personalized treatment options, and real-time monitoring of Manufacturing processes. Despite its transformative potential, the integration of AI faces Challenges related to data quality, regulatory compliance, technical hurdles, and workforce skills. However, collaborative efforts between industry and academia, coupled with continuous Improvement models, offer promising opportunities for the future of AI in pharmaceuticals. This Comprehensive overview highlights the promise of AI to revolutionize drug development andManufacturing, paving the way for innovative treatments and improved healthcare outcomes.

Keywords: AI, drug development, precision medicine, clinical trials, manufacturing optimization, Machine learning, regulatory compliance, collaborative innovation.

I. INTRODUCTION:

AI is transforming technology by making machines smart enough to do tasks that usually require human thinking. It uses different methods like machine learning, language understanding, and robots to help machines learn from data, recognize patterns, and make decisions. This has improved many fields such as healthcare, finance, and transportation, making them faster and more efficient.In the pharmaceutical industry, AI is playing an important role. It is helping to speed up the process of creating new medicines by finding better ways to test and develop drugs. AI also makes production more efficient, which helps save time and reduce costs. This means that medicines can be made more quickly and at a lower price, benefiting both companies and patients.This review article explores the integration of AI into drug Development and manufacturing, highlighting the advancements and challenges associated with This technological evolution.[1,2]

❖ IMPORTANCE OF AI IN THE PHARMACEUTICAL INDUSTRY:

1.Accelerated Drug Discovery:.AI can quickly examine a lot of biological information to discover potential drugs and guess how well they will work.Machine learning algorithms can Process data from existing drugs, genomic information, and scientific literature to identify new Therapeutic targets and propose novel compounds.[3]

2.Enhanced Precision and Personalization:AI helps create personalized medicine by looking at each patient's data, like their genes, lifestyle, and health history, to find the best treatment for them.Personalized medicine can improve patient outcomes and reduce Adverse drug reactions.[3]

3. Improved Clinical Trials: AI can help design adaptive clinical trials that adjust parameters based on Interim results, increasing the likelihood of successful outcomes. This leads to faster, more cost-Effective trials and accelerates the time to market for new drugs.[3]

4. Efficient Drug Manufacturing:AI enhances drug manufacturing processes through automation, predictive maintenance, and Quality control.In manufacturing, AI systems can monitor production lines in real-time, predicting Equipment failures before they occur and ensuring continuous, efficient operations. Furthermore, AI-driven quality control Systems can detect anomalies and ensure that products meet stringent regulatory standards, Minimizing the risk of defects.[3]

---

5. Data-Driven Decision Making:AI supports data-driven decision-making throughout the pharmaceutical industry. By integrating And analyzing data from diverse sources, AI provides insights that can guide research and Development, marketing strategies, and regulatory compliance. AI also aids in post-market surveillance by Analyzing real-world data to monitor drug safety and effectiveness, enabling timely interventions If adverse effects are detected.[4]

6. Cost Reduction and Efficiency:AI contributes to significant cost savings and efficiency gains in the pharmaceutical industry.These savings can be reinvested into Further research and development, fostering innovation and enhancing the industry's overall Productivity.[4]

7. Regulatory Compliance and Risk Management:AI can analyze lots of data fast, making drug discovery quicker, improving treatments for individuals, and making clinical trials and production more efficient. It helps companies make better choices, cut costs, and followregulations. As AI gets better, it will play a important role in the pharmaceutical industry, leading to new breakthroughs and better healthcare..[5,6]

❖ **OBJECTIVES OF THE REVIEW ARTICLE:**

1.To Explore the Integration of AI in Drug Development:AI is changing drug development in many ways, starting from the discovery stage to clinical trials.

2.To Assess AI's Role in Drug Manufacturing: Investigate the applications of AI in enhancing manufacturing processes, including Process optimization, real-time monitoring, and quality control.

3. To Identify and Analyze Key Advancements: Advancements in AI technologies big impact in the Pharmaceutical industry, such as machine learning, natural language processing, And robotics.

4. To Address Challenges and Limitations: Identify the main challenges and limitations associated with integrating AI into Drug development and manufacturing.

5. To Highlight Future Directions and Opportunities: Outline potential future developments and opportunities for AI in the Pharmaceutical industry.

6. To Provide a Comprehensive Overview: Offer a thorough and balanced overview of the current state of AI integration in the Pharmaceutical industry.

❖ **AI in Drug Development:**
(A)Drug Discovery:

➤ **AI in Target Identification:Accelerating Target Identification:**
o AI techniques like machine learning and deep learning are revolutionizing the Identification of drug targets by analyzing large-scale genomic and proteomic data. This significantly speeds up the process and increases success rates.
o AI models using toolkits like Intel OpenVINO can automate drug discovery, Reducing clinical trial times from years to months by identifying drug reactants Through custom object detection techniques.
o Machine learning algorithms help discover macromolecular targets by analyzing Bioactivity data, prioritizing biochemical screens for drug developments.[7]

Image: Enormous Amount Of Data

➤ **AI-Driven Virtual Screening:Enhancing Virtual Screening Efficiency:**
o Machine learning techniques, such as convolutional neural networks, improve the Accuracy and efficiency of virtual screening, especially for complex diseases like Alzheimer's.
o Advanced structure-based virtual screening methods,including ensemble-average Free energy estimation,enhance the accuracy of identifying potential drug Candidate.[7]

Image:AI Powered Virtual Screening

➤ **AI Applications in Drug Discovery:**
o AlphaFold's AI-driven protein structure predictions have facilitated the discovery Of novel drug targets and inhibitors, like a cyclin-dependent kinase 20 (CDK20) Inhibitor, accelerating the drug development process.
o AI has helped find targets for cancer treatments by studying complex cell processes and molecules.
o AI-powered platforms like PandaOmics and Chemistry42 use structure-based Virtual screening to generate and test molecules rapidly, resulting in the Identification of potent drug candidates.[7]

(B)Preclinical Development:
➤ **AI for Predicting Pharmacokinetics and Pharmacodynamics:Improving PK/PD Predictions:**
o AI models significantly enhance the prediction of pharmacokinetic (PK) and Pharmacodynamics (PD) profiles, using in vitro and in vivo data to forecast human Responses. This helps in identifying safe and effective dosing regimens early in the Drug development process.
o Machine learning algorithms help to predict how drug absorbed,distributed,Metabolized, and excreted(ADME) in the body.

➤ **AI in Toxicity Prediction:Enhancing Toxicity Prediction Accuracy:**
o Machine learning techniques, such as deep learning and random forests, help predict how harmful a drug could be by analyzing its chemical structure and gene activity.These methods improve accuracy and efficiency in Identifying potentially toxic compounds before clinical trials.

o AI models trained on gene expression data can predict developmental and organ-Specific toxicities, such as neurotoxicity and hepatotoxicity, with high accuracy. This reduces reliance on animal testing and enhances safety assessments.

➤ **AI Applications in Preclinical Stages:**
o AI-driven models have been successfully used to predict kidney dysfunction and Other toxicities in animal models based on human cell line data, improving the Accuracy of preclinical safety assessments.
o AI-based platforms for virtual screening and toxicity prediction have been Integrated into the drug development pipeline, helping to identify safe and effective Drug candidates more efficiently.[8-11]

(C) Clinical Trials:
➤ **AI in Patient Recruitment and Selection:Enhancing Patient Recruitment:**
o AI significantly improves patient recruitment by using machine learning algorithms To analyze electronic health records (EHRs) and identify eligible candidates more Efficiently.
o Natural language processing (NLP) models like TrialGPT assist in matching Patients to trials by predicting eligibility based on free-text patient notes, enhancing Recruitment accuracy and reducing time.
➤ **AI for Trial Design Optimization:Optimizing Trial Design:**
o AI algorithms, such as genetic algorithms, optimize trial designs by determining The best blood sampling schedules and dose group allocations, reducing the number Of required subjects without compromising accuracy.
o AI models analyze historical data and simulate different trial scenarios to optimize Inclusion

criteria, improving the generalizability and efficiency of trials.

➢ **AI in Monitoring and Analyzing Trial Data:Enhancing Data Monitoring:**
o AI-powered tools like AiCure on mobile devices monitor medication adherence and Detect non-adherence, providing accurate real-time data for better trial outcomes.
o Systems like TrialView use visual analytics and graph AI to integrate and analyze Temporal event data, enabling interactive exploration of individual and group-level Trial data, improving decision-making process.


Image:AI And Ml In Clinical Trials

➢ **AI in application clinical Trials:**
o AI-driven platforms have demonstrated increased enrollment rates in trials, such as The EMBOLISE trial, where AI screening led to a 36% increase in patient Enrollment.
o AI applications in trials for conditions like schizophrenia showed higher adherenceRates, demonstrating the technology's potential to improve trial accuracy and reduceDropout rates.[12-15]

❖ **AI in Drug Manufacturing:**
(A)Process Optimization:
➢ **AI for Process Design and Optimization:**

Enhancing Design:
o AI methods like machine learning are used to study large amounts of biological data. This helps design drugs more efficiently by finding disease targets and predicting how the drugs will work.Interactions with potential drug candidates.
o AI optimizes research and development processes, reducing costs by assisting in Experimental design, predicting pharmacokinetics, and toxicity, and facilitating Personalized medicine approaches through real-world patient data analysis.

➢ **AI in Real-Time Monitoring and Control:**
Improving Manufacturing Control:
o AI systems are employed for real-time control of process plants, monitoring the State of the plant and assisting operators in controlling difficult processes and Diagnosing problems.
o AI-based systems in semiconductor manufacturing analyze big data in real-time, Predicting chemical states and alerting managers when deviations occur, thus Preventing equipment contamination and wafer scrap.

➢ **AI application in process optimization:**
o In the pharmaceutical industry, AI enhances the 3D printing process by predicting Key fabrication parameters, improving the efficiency of producing personalized Drug-loaded formulations.
o In biopharmaceutical manufacturing, AI models address the challenge of limited Production history by generating in silico batches, ensuring comprehensive real-Time

monitoring and improving process and product performance.

(B) Quality Control:

➢ **AI in Quality Assurance and Control:Enhancing QA/QC:**
o AI systems, like machine learning and deep learning, are used to automatically check pharmaceutical products for defects.This makes inspections faster and more accurate, reducing the need for manual checks.
o AI can also monitor production in real-time to ensure products meet quality standards and catch any problems before defective products are released.[16]

➢ **AI-Driven Predictive Maintenance:Improving Predictive Maintenance:**
o Predictive maintenance uses AI to analyze data from equipment sensors, predicting when machines might break down. This helps reduce repair time and costs while making machines last longer.
o Machine learning models, like decision trees and neural networks, are used to predict problems, improving reliability and efficiency in manufacturing.

➢ **AI in application in Quality Control:**
o AI-based visual inspection systems in the automotive and electronics industries Have significantly improved defect detection rates, demonstrating the potential for Similar success in pharmaceutical manufacturing.
o AI-driven predictive maintenance strategies have been implemented in various Industries, including aerospace and energy, showing substantial reductions in Maintenance costs and improvements in equipment reliability.[17]

(C) Supply Chain Management:

➢ **AI in Demand Forecasting:Enhancing Demand Forecasting:**
o AI algorithms look at past sales data, market trends, and other factors to predict future demand. This helps pharmaceutical companies keep the right amount of stock, avoiding running out of products or having too much.

➢ **AI for Logistics and Distribution Optimization:Optimizing Logistics and Distribution:**
o AI-driven logistics systems optimize delivery routes, manage warehouse Operations, and

track shipments in real-time. This ensures timely delivery of Products and reduces transportation costs.

➢ **AI application in Supply Chain Management:**
o Big pharmaceutical companies like Pfizer and Merck use AI to improve their supply chains, making their delivery and logistics faster and more efficient, which helps them save money.
o AI technologies have been used to enhance the accuracy, speed, and efficiency of Supply chain management in various industries, showcasing their potential benefits For pharmaceutical supply chains.[18,19]

❖ **ADVANCEMENTS IN AI TECHNOLOGIES FOR PHARMACY**
(A)Machine Learning and Deep Learning:
1.Target Identification and Validation:AI models predict potential drug targets by analyzing biological data, leading to the Discovery of new drug candidates.

2. Drug Design and Discovery: Machine learning algorithms are used to design new molecules, optimize lead Compoundsand predict their properties.

3. Clinical Trials:AI assists in patient recruitment by identifying eligible candidates from large Datasets, optimizing trial design, and monitoring trial data in real-time.Machine learning models predict patient responses and optimize dosing regimens, Improving trial outcomes.[20,21]

(B)Natural Language Processing (NLP):
➢ **NLP for Literature Review and Data Extraction**
1. **Automating Systematic Reviews:**NLP models extract and synthesize data from scientific literature, accelerating the Reviewprocess and ensuring comprehensive data collection.
2. **Data Extraction from Clinical Records:**NLP algorithms process unstructured clinical data to extract relevant information, Aiding in real-time data analysis and decision-making.

➢ **AI in Regulatory Submissions**
1. **Enhancing Submissions:**AI tools, such as generative AI models, streamline the preparation of regulatory Documents, ensuring accuracy and consistency.

2. **Classifying Regulatory Documents:**NLP techniques, such as BERT, automatically classify section of regulatory documents, improving the efficiency of review process.

(C)Integration of Omics Data:
➢ **AI in Genomics, Proteomics, and Metabolomics**
1. **Data Integration:**AI combines genetic, protein, and metabolic data to find markers of diseases, predict how diseases will progress, and create personalized treatment plans.
2. **Predictive Modeling:**Machine learning models analyze omics data to predict patient responses and Optimize therapeutic strategies.

➢ **Case Studies of Omics Data Integration**
1. **Cancer Research**:AI models integrate genomic data to identify cancer biomarkers, aiding in early Detection and targeted therapy development.
2. **Metabolic Disorders:**Integrating metabolomic data with AI models helps in understanding metabolic Pathways and developing targeted treatments.

(D) Robotics and Automation:AI in Lab Automation:
1. **Enhancing Laboratory Processes:**AI-powered robots automate routine laboratory tasks, increasing efficiency and Reducing human error.
2. **High-Throughput Screening:**Robotics combined with AI enables high-throughput screening of drug candidates, Accelerating the drug discovery process.
➢ **Robotic Applications in Manufacturing:**

1. **Pharmaceutical Manufacturing:**AI-driven robots optimize manufacturing processes, ensuring consistent quality And reducing production costs.
2. **Personalized Medicine:**Robotics in combination with AI enables the production of personalized drug Formulations, tailored to individual patient needs.

❖ **CHALLENGES AND LIMITATIONS OF AI IN DRUG DEVELOPMENT**
(A)Data Quality and Availability:
1.Data Quality: Good quality data is crucial for using AI effectively in drug development.Poor data quality, including inaccuracies, missing values, and Inconsistencies, can lead to unreliable AI models.

2.Data Completeness: Incomplete datasets hinder the ability of AI models to make accurate predictions. Ensuring that datasets are comprehensive and representative of diverse populations Is crucial.
3.Data Standardization: Lack of standardization across different data sources creates challenges in Integrating and comparing data, which is necessary for building robust AI Models.[22]

(B)Regulatory and Ethical Considerations:
➢ **Regulatory Hurdles for AI Integration:**
1.Comliance and Validation: Regulatory agencies require thorough validation and documentation of AI models To ensure their safety and efficacy, which can be a complex and time-consuming Process.
2.Approval Processes: The approval processes for AI-driven solutions can be lengthy, as regulators need To understand and trust the underlying algorithms and their decision-making Processes.

➢ **Ethical Concerns and Data Privacy**
1.Data Privacy: Protecting patient privacy is paramount. AI systems must comply with data Protection regulation's such as GDPR and HIPAA to safeguard sensitive Information.
2.Ethical Concerns: Ethical considerations include ensuring that AI models do not introduce or Perpetuate biases, and that their use does not lead to discrimination or unfair Treatment of certain patient groups.[23]

(C)Technical Challenges:
➢ **Combining AI with Current Systems:**
1.Compatibility: Integrating AI with existing healthcare and pharmaceutical systems can be Challenging due to differences in data formats, standards, and technologies.
2.Interoperability: Ensuring seamless communication and data exchange between AI systems and Existing infrastructure is critical for effective implementation.Scalability and Reliability of AI Solutions.
3.Scalability:AI solutions need to be able to grow and manage large amounts of data and complex tasks, which requires strong computing power and infrastructure.
4.Reliability: Ensuring that AI models are reliable and produce consistent results across different Scenarios and datasets is essential for their acceptance and use in clinical settings.

(D)Workforce and Skills Gap:
➤ **Need for Skilled Personnel in AI and Data Science:**
1.Skill Shortage: There is a growing need for professionals skilled in AI, machine learning, and data Science. The shortage of such expertise can limit the adoption and development of AI-driven solutions.
2.Multidisciplinary Expertise: Successful implementation of AI in drug development requires a combination of Domain knowledge in pharmaceuticals and technical expertise in AI, which can be Hard to find.[24]

➤ **Training and Development Challenges**
1.Continuous Learning:AI technologies are rapidly evolving, necessitating continuous learning and training For personnel to stay updated with the latest advancements.
2.Educational Programs: Creating detailed education and training programs is important to help professionals gain the skills they need and close the skills gap..[25,26]

❖ **Future Directions and Opportunities in AI for Pharma:**
(A)Personalized Medicine:
➤ **AI in Developing Personalized Treatment Plans:**
1.Tailored Treatments:
o AI AI helps create personalized treatment plans by looking at each patient's unique genetic and molecular information. This ensures the right treatment is given at the right time and dose.
o AI can predict how a patient will respond to a drug based on their genetic data, making treatments safer and more effective.
o In cancer care, AI is especially helpful in choosing the best treatments based on a patient's individual genetic makeup..[27]

(B)Collaborative Efforts:
➤ **Industry-Academia Partnerships**:
1.Research Synergy: Collaborations between industry and academia foster innovation by combining Practical insights with advanced research. These partnerships accelerate the Development of new AI technologies and their application in drug development.
2.Bridging Gaps: Public-private partnerships play a crucial role in overcoming regulatory and Funding challenges. These collaborations facilitate the translation of AI research Into practical applications in drug development and healthcare.[28]

(C)Continuous Improvement:
➤ **Continuous Learning Models and Adaptive AI:**
1.Dynamic AI Systems:
o Continuous learning models help AI systems adjust and improve as they get new information and learn more about medicine.This ensures that AI-driven solutions remain accurate and Relevant over time.[29]

➤ **AI in Post-Market Surveillance**
1.Monitoring and Safety:
o AI improves post-market drug safety by analyzing data from sources like health records and patient reports to quickly spot problems, such as side effects.[30-33]

II. CONCLUSION:

In conclusion, the integration of Artificial Intelligence (AI) into the pharmaceutical Industry holds immense promise for revolutionizing drug development and manufacturing Processes. AI uses machine learning, language processing, and robotics to speed up finding treatment targets, create personalized medicines, simplify clinical trials, and improve manufacturing processes.Despite facing challenges such as data quality, regulatory Compliance, and workforce skills, collaborative efforts between industry and academia, coupled With continuous improvement models, offer opportunities for overcoming these hurdles.As AI technology keeps improving, it will play a important role in pharmaceuticals, leading to new treatments and better healthcare results.

REFERENCES:

[1]. Adams, S. (2019) Artificial intelligence for drug discovery, biomarker development, and Generationofnovel chemistry.
[2]. Aliper, A., Plis, S., Artemov, A., Ulloa, A., Mamoshina, P., &Zhavoronkov, A. (2016). Deep learning applications for predicting pharmacological properties of drugs and drug Repurposing using transcriptomic data.Molecular Pharmaceutics, 13(7), 2524–2530.
[3]. Arús-Pous, J., Johansson, S. V., Prykhodko, O., Bjerrum, E. J., Tyrchan, C., &Reymond,J. L. (2019). Randomized SMILES strings improve the quality of

molecular generative Models. Journal of Chemical Information and Modeling, 59(12), 1208–1214.

[4]. Blasiak, A., Khatri, A., Ferreira, R., Olczak, J., &Damaševičius, R. (2020). Review of Artificial intelligence techniques in imaging data acquisition, segmentation, and diagnosis For covid-19. IEEE Access, 8, 99516–99530.

[5]. Boureau, Y.-L., & Ponce, J. (2010). A theoretical analysis of feature pooling in visual Recognition.In Proceedings of the 23rd International Conference on Neural Information Processing Systems (pp. 221–229).

[6]. Bradley, A. R., Rose, A. S., Pavelka, A., Valasatava, Y., Duarte, J. M., Prlić, A., & Rose, P. W. (2017). MMTF—An efficient file format for the transmission, visualization, and Analysis of macromolecular structures. PLOS Computational Biology, 13(6), e1005575.

[7]. Brittain, R., Penney, M., Hakala, M., Dobler, G., Parker, T., Tironi, P., & Heinemann, A. (2020). AstraZeneca Pharma Intelligence Data Science and AI: Building AI-powered data Products. Journal of Computational Chemistry, 41(12), 1142–1151.

[8]. Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., Ferrero, E., Agapow, P. M., Zietz, M., Hoffman, M. M., &Xie, W. (2018). Opportunities And obstacles for deep learning in biology and medicine. Journal of the Royal Society Interface, 15(141), 20170387.

[9]. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793–795.

[10]. Cramer, R. D., Patterson, D. E., &Bunce, J. D. (1988). Comparative molecular field Analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. Journal of The American Chemical Society, 110(18), 5959–5967.

[11]. Dahlin, J. L., Nissink, J. W., Strasser, J. M., Francis, S., Higgins, L., Zhou, H., Zhang, Z., & Walters, M. A. (2015). PAINS in the assay: Chemical mechanisms of assay interference And promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. Journal of Medicinal Chemistry, 58(5), 2091–2113.

[12]. Damaševičius, R., &Maskeliūnas, R. (2018). A review of artificial intelligence in Healthcare: Challenges for the next decade. Frontiers in Artificial Intelligence, 1, 1–12.

[13]. DeepMind. (2020). AlphaFold: Using AI for scientific discovery.

[14]. Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., &Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118.

[15]. Gao, K., Nguyen, D. D., Sankaranarayanan, M., Ebert, S., Kelkar, A., Louttit, J. B., Solovyev, V., &Gao, Y. (2019). Quantum machine learning in feature Hilbert spaces.Physical Review X, 9(3), 031045.

[16]. Goh, G. B., Hodas, N. O., & Vishnu, A. (2017). Deep learning for computational chemistry. Journal of Computational Chemistry, 38(16), 1291–1307.

[17]. Haghighi, M., &Asgari, Y. (2020). Review of applications of deep learning and machine Learning in drug discovery and design. Journal of Drug Delivery Science and Technology, 59, 101896.

[18]. Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., & Coleman, R. G. (2012). ZINC: A free tool to discover chemistry for biology. Journal of Chemical Information and Modeling, 52(7), 1757–1768.

[19]. Kang, S., Peng, S., Yang, K., & Yang, C. (2019). DeepCDpred: Interpretable prediction of Continuous and discontinuous protein binding modes by use of convolutional neural Networks. Physical Review E, 100(1), 012414.

[20]. Khemchandani, R., &Bagale, U. D. (2019). Artificial intelligence in clinical trials. Perspectives in Clinical Research, 10(3), 101–105.

[21]. Kingma, D. P., & Ba, J. (2014). Adam: A method for stochastic optimization. arXiv preprintarXiv:1412.6980.

[22]. Kortylewski, A., Wiggins, C. H., & Ling, H. (2018). Deep learning for single-molecule Science.Nanotechnology, 29(43), 432001.

[23]. Kryshtafovych, A., Schwede, T., Topf, M., Fidelis, K., Moult, J., & Critical

Assessment of Structure Prediction (CASP). (2019). Assessment of model accuracy estimations in CASP13. Proteins: Structure, Function, and Bioinformatics, 87(12), 1283–1292

[24]. Landrum, G. (2006). RDKit: Open-source cheminformatics.

[25]. Lavecchia, A. (2015). Machine-learning approaches in drug discovery: Methods and Applications. Drug Discovery Today, 20(3), 318–331.

[26]. LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. Nature, 521(7553), 436–444.

[27]. Lusci, A., Pollastri, G., &Baldi, P. (2013). Deep architectures and deep learning in Chemoinformatics: The prediction of aqueous solubility for drug-like molecules. Journal of Chemical Information and Modeling, 53(7), 1563–1575.

[28]. Ma, J., Sheridan, R. P., Liaw, A., Dahl, G. E., Svetnik, V., &DeepChem Development Team. (2015). Deep neural nets as a method for quantitative structure-activity relationships. Journal of Chemical Information and Modeling, 55(2), 263–274.

[29]. Martin, E. J., &Polyakov, V. R. (2019). AI in drug discovery: What is realistic, what are Illusions? Part 2: A discussion on chemical and biological data. Drug Discovery Today, 24(2), 511–515.

[30]. McInnes, L., Healy, J., & Melville, J. (2018). UMAP: Uniform manifold approximation and Projection for dimension reduction. arXiv preprint arXiv:1802.03426.

[31]. Mobley, D. L., & Gilson, M. K. (2017). Predicting binding free energies: Frontiers and Benchmarks. Annual Review of Biophysics, 46(1), 531–558.

[32]. Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Prettenhofer, P., Weiss, R., Dubourg, V., &Vanderplas, J. (2011).Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research, 12, 2825–2830.

[33]. Pérez-Sianes, J., Ochoa, J. J., & Rueda, L. (2019). Towards the comprehensive computer-aided drug design. Drug Discovery Today, 24(6)